Transplant Oncology: Immuno-Oncology for Transplant Patients

Organized By:

Transplant Oncology Workgroup



Start Time:

October 1, 2022 9:00 am EST

End Time:

October 1, 2022 12:05 pm EST

Course Overview

Solid organ transplant recipients are at 3-10 times higher risk of cancer compared to non-transplant patients, due to long-standing immunosuppression. Cancer immunotherapy has become a standard therapy for many cancers, but its use in transplant patients is challenging because of safety and efficacy concerns.

While there has been a growing data on Immuno-Oncology (IO) in transplant population, the consensus on IO use in this vulnerable population is lacking. The goals of our conference are to understand the cancer burden in transplant recipients, to learn up-to-date cancer treatment options (especially IO’s) for transplant patients, and to learn patients’ perspectives from those living with cancer post-transplants.

Learning Objectives

  1. Understand the cancer burden in transplant recipients
  2. Learn up-to-date cancer treatment options for transplant patients
  3. Learn patients’ perspectives from those living with cancer post-transplant

Target Audience

This course is targeted to transplant clinicians (nephrologists, hepatologists, surgeons, advanced practitioners, nurses, social workers), oncologists, as well as transplant recipients and their caregivers.

Course Faculty  

Course Director

Naoka Murakami
Assistant Professor, Harvard Medical School
Associate Physician, Transplant Nephrology, Brigham and Women’s Hospital

Course Planners

Ala Abudeyyeh
MD Anderson Cancer Center
Christopher Blosser
University Washington, Fred Hutch Cancer Institute
Farhad Danesh
MD Anderson Cancer Center
Sandra Harrmann
Mayo Clinic
Edgar Jaime
Memorial Sloan Kettering Cancer Center (MSKCC)
Kenar Jhaveri
Hofstra/Northwell Health
Aleksandra Kukla
Mayo Clinic
Sheron Latcha
Nelson Leung
Mayo Clinic


Opening Remarks

Immunotherapy for Kidney Transplant Recipients

Christopher Blosser
Christopher Blosser
Nephrology, University of Washington, Seattle

“Cancer Risk in Kidney Transplant Patients”
Naoka Murakami
Nephrology, Brigham and Women’s Hospital, Boston

Immune Checkpoint Blockade for Kidney Transplant Patients” – International Society of Nephrology (ISN) designated Speaker

How to Treat Cancer in Transplant Patients

Evan Lipson
Oncology, Johns Hopkins University Hospital

Immunomodulatory Therapy for Kidney Transplant Recipients with Advanced Cutaneous Cancers
Glenn Hanna
Glenn Hanna
Oncology, Dana Farber Cancer Institute

Immune Checkpoint Blockade for Renal Transplant Recipients with Cutaneous Squamous Cell Carcinoma
Sarah Nikiforow
Sarah Nikiforow
Oncology, Dana Farber Cancer Institute

Cellular Therapies for Transplant Patients
Adi Diab
Adi Diab
Oncology, MD Anderson Cancer Center

ImmunoOncology and Biomarkers

Immune Checkpoint Blockade for Liver Transplant Recipients

Kymberly Watt
Kymberly Watt
Hepatology, Mayo Clinic

Transplant Hepatologist’s Perspective
Maen Abdelrahim
Maen Abdelrahim
Oncology, Houston Methodist Hospital

Transplant Oncologist’s Perspective

Patients’ Perspectives (Patient Roundtable)

Closing Remarks


Registration for this course is open. Zoom link will be emailed to the registration email address about 1 week before the event date.